Patients with B-cell-derived malignancies are at increased risk of severe coronavirus disease 2019 (COVID-19) due to the inherent immune dysfunction and/or treatment. To protect patients in general and patients with B-cell-derived malignancies in particular from COVID-19, management of these patients was changed toward virtual consultations during the pandemic. Whether the COVID-19 pandemic itself and/or changes in management have led to excess mortality among hematological patients during the COVID-19 pandemic in Denmark has not yet been investigated.